2 results
Approved WMOWill not start
Primary:To estimate the treatment effect of emactuzumab on objective response rate (ORR) by 6 months from initiation of therapy in the blinded phase compared to placeboSecondary:the effect of emactuzumab on clinical outcome assessments (COAs) for:o…
Approved WMOPending
Primary:To determine the efficacy of INCB000928 for the prevention of new HO in participants with FOP.Key Secondary:To further evaluate the efficacy of INCB000928 in the reduction of flares and improvement in flare-related symptoms.Secondary:- To…